A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc.
University of Manchester
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ankara University
Hospices Civils de Lyon
The Christie NHS Foundation Trust
University Hospital of North Norway
Maastricht Radiation Oncology
Threshold Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Threshold Pharmaceuticals
Siemens Molecular Imaging
Novacea